Zobrazeno 1 - 10
of 34
pro vyhledávání: '"35"'
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Testicular Self-Examination (TSE) causes earlier diagnosis of Testicular cancer (TC). Hence, all men aged between15 to 35 years should perform TSE every month. This study aims to survey the effect of educational intervention based on healt
Autor:
Eryk Kapusta, Paweł Skorek, Izabela Witek-Motyl, Konrad Stepien, Kinga Kwiecinska, Sławomir Kroczka, Szymon Skoczeń, Agnieszka Biedron
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
Background One of the greatest success of pediatric hematology is a prominent improvement of survival in acute lymphoblastic leukemia (ALL). Therefore, special attention needs to be paid to long-term side effects of the treatment such as neurotoxicit
Autor:
Xiaodong Teng, Jing Zhang, Qian Shen, He Cao, Xiao Teng, Zhen Chen, Yanting Yuan, Huisong Luo, Ke Huang
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Background Lung cancer in young patients is rare and has unique clinicopathological features. However, the molecular features of lung cancer in these patients are unclear. In this study, we aimed to describe the molecular features and outcomes of lun
Autor:
Preisler, Sarah Nørgaard, Rebolj, Matejka, Ejegod, Ditte Møller, Lynge, Elsebeth, Rygaard, Carsten, Bonde, Jesper
Publikováno v:
BMC Cancer
Preisler, S N, Rebolj, M, Ejegod, D M, Lynge, E, Rygaard, C & Bonde, J 2016, ' Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays : split-sample study ', B M C Cancer, vol. 16, 510 . https://doi.org/10.1186/s12885-016-2518-4
Preisler, S N, Rebolj, M, Ejegod, D M, Lynge, E, Rygaard, C & Bonde, J 2016, ' Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays : split-sample study ', B M C Cancer, vol. 16, 510 . https://doi.org/10.1186/s12885-016-2518-4
BACKGROUND:High-risk Human Papillomavirus (HPV) testing is replacing cytology in cervical cancer screening as it is more sensitive for preinvasive cervical lesions. However, the bottleneck of HPV testing is the many false positive test results (posit
Autor:
Yuqing Qu, Jan P. A. Baak, Xianrong Zhou, Menghan Zhu, Weiwei Feng, Qing Wang, Long Sui, Yuan He
Publikováno v:
BMC Cancer
Background In 5–20 % of patients with cervical high-grade squamous intraepithelial lesion (HSIL), a positive margin after the loop electrosurgical excision procedure (LEEP) is associated with persistence/recurrence, but the prognostic value of othe
Autor:
Fumitaka Kikkawa, Takayuki Murao, Shunichi Ishihara, Dai Okazaki, Yoshiyuki Itoh, Kaoru Uchiyama, Takeshi Kodaira, Takahiro Yamaguchi, Taro Murai, Yuuki Takase, Shinji Naganawa, Mariko Kawamura, Mika Mizuno, Yuta Shibamoto, Yutaro Koide
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background Standard treatments for small cell carcinoma of the cervix (SCCC) have not been established. In this study, we aimed to estimate the optimal treatment strategy for SCCC. Methods This was a multicenter retrospective study. Medical records o
Autor:
Eduardo Tormo, Joan Climent, M. I. Martínez, Jaime Ferrer-Lozano, Elisa Alonso-Yuste, Ana Bosch, Pilar Eroles, Lorena Peiró-Chova, Beatriz Martinez-Delgado, Jose Alejandro Perez-Fidalgo, Maria Peña-Chilet, Ana Lluch, Sara S. Oltra, Octavio Burgues, Gloria Ribas
Publikováno v:
Repisalud
Instituto de Salud Carlos III (ISCIII)
BMC Cancer
Instituto de Salud Carlos III (ISCIII)
BMC Cancer
BACKGROUND: Breast cancer is rarely diagnosed in very young women (35 years old or younger), and it often presents with distinct clinical-pathological features related to a more aggressive phenotype and worse prognosis when diagnosed at this early ag
Autor:
Marcel Verheij, Frank J. P. Hoebers, Teresa Herlestam, J. Heukelom, Eric Deutsch, Coen R.N. Rasch, N. Slevin, Jordi Giralt, Wouter V. Vogel, Philippe Lambin, Harry Bartelink, Michiel W. M. van den Brekel, Jan-Jakob Sonke, Olga Hamming
Publikováno v:
BMC Cancer, 13. BioMed Central
Heukelom, J, Hamming, O, Bartelink, H, Hoebers, F, Giralt, J, Herlestam, T, Verheij, M, van den Brekel, M, Vogel, W, Slevin, N, Deutsch, E, Sonke, J J, Lambin, P & Rasch, C 2013, ' Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. ', BMC Cancer, vol. 13 . https://doi.org/10.1186/1471-2407-13-84
BMC Cancer, 13:84. BioMed Central Ltd
BMC Cancer, 13. BMC
BMC cancer, 13. BioMed Central
BMC Cancer
Heukelom, J, Hamming, O, Bartelink, H, Hoebers, F, Giralt, J, Herlestam, T, Verheij, M, van den Brekel, M, Vogel, W, Slevin, N, Deutsch, E, Sonke, J J, Lambin, P & Rasch, C 2013, ' Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. ', BMC Cancer, vol. 13 . https://doi.org/10.1186/1471-2407-13-84
BMC Cancer, 13:84. BioMed Central Ltd
BMC Cancer, 13. BMC
BMC cancer, 13. BioMed Central
BMC Cancer
Background Failure of locoregional control is the main cause of recurrence in advanced head and neck cancer. This multi-center trial aims to improve outcome in two ways. Firstly, by redistribution of the radiation dose to the metabolically most FDG-P
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 90 (2012)
BMC Cancer, Vol 12, Iss 1, p 90 (2012)
Background Gastrointestinal stromal tumors (GIST), one of the most common mesenchymal tumors of the gastrointestinal tract, prior to routine immunohistochemical staining and the introduction of tyrosine kinase inhibitors, were often mistaken for neop
Autor:
Gaston J H Franssen, Tessa Brabander, Robin P. Peeters, Leo J. Hofland, Francien H. van Nederveen, Boen L. R. Kam, Carolien M. Beukhof, Yolanda B. de Rijke, Lideke A. C. Fröberg, Marie-Louise F. van Velthuysen, W. Edward Visser, Wouter W. de Herder
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer, 19:325. BioMed Central Ltd.
BMC Cancer
BMC Cancer, 19:325. BioMed Central Ltd.
BMC Cancer
Background For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT),